SCHEMBL1481692

SCHEMBL1481692

CCn1cc(-c2ccc(Cl)cc2Cl)nc1C=Cc1cc(-c2ccc(O)cc2)ccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
LMNA P02545 1/20 0.34
DPP4 P27487 3/20 0.33
DPP8 Q6V1X1 2/20 0.33
MARS1 P56192 1/20 0.33
KCNA3 P22001 1/20 0.32
ALPL P05186 1/20 0.32
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
CNR1 P21554 4/20 0.31
CNR2 P34972 2/20 0.31
DPP9 Q86TI2 1/20 0.31
CRHR1 P34998 1/20 0.30
ESR1 P03372 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1481688 1.00 MAPT (0.41) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1480556 0.93 MEN1 (0.40) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1480554 0.93 MEN1 (0.40) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1481879 0.88 MEN1 (0.39) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1481881 0.88 MEN1 (0.39) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1480644 0.87 MEN1 (0.45) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1480642 0.87 MEN1 (0.45) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1481672 0.85 MAPT (0.35) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1481670 0.85 MAPT (0.35) MAPTMEN1KMT2ASMN1; SMN2PTGS1
SCHEMBL1484093 0.85 MEN1 (0.41) MAPTMEN1KMT2ASMN1; SMN2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885MEN1 3467/4885KMT2A 1996/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MAPT 3558/4885MEN1 3467/4885KMT2A 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.